NASDAQ OMX

IPsoft Launches Amelia Healthcare Practice to Transform the Healthcare Workforce and Patient Experience with Cognitive AI

Dela

NEW YORK, Sept. 26, 2017 (GLOBE NEWSWIRE) -- IPsoft, the leading digital labor company, is to launch a vertically focused portfolio of solutions for the healthcare industry based on its AI platform, Amelia. A series of Amelia Health Agent offerings are under development in a program of co-collaboration with healthcare providers, health systems, health insurers and life sciences organizations. The first releases will target high volume processes and interactions that will deliver tangible improvements for providers, insurers, carers and patients. 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/04fe91f2-5d18-475f-b43e-7d1183aaba1b

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4758c05a-915d-4278-8f55-6ed323f7649f

A video accompanying this announcement is available at 
http://www.globenewswire.com/NewsRoom/AttachmentNg/1be90122-0c3d-499e-9a10-80da9d5262b5

The new practice builds on the positive results of Amelia implementations across industries to target the healthcare AI market, which is expected to reach $6.6 billion by 20211. 

"We have seen the hype about AI's ability to find cures for major diseases overnight.  Now it is time to recover AI's reputation by applying advanced cognitive technology to the daily operations of the sector in order to provide demonstrable benefits to patients and the organizations who treat them," said Chetan Dube, IPsoft President and CEO.  

In order to develop and lead this new global practice, IPsoft has appointed David Champeaux as its global Cognitive Director, Healthcare Solutions. David has deep experience in designing and leading technology-enabled transformations within the healthcare sector both in his previous role as a Partner in McKinsey & Company's Healthcare practice and McKinsey Digital, where he served clients in Europe, Australia and the US, and as Managing Director leading Accenture's UK Healthcare Strategy practice.

"Routine cognitive processes can take up to 51% of a nurse's and 17% of a doctor's time - which is frustrating when Health Systems struggle with affordability and workforce shortages and patients complain about access. With Amelia's unique combination of human-like conversational intelligence, advanced analytics and dynamic processes execution, we finally have the opportunity to transform healthcare by freeing up its human capital - addressing challenges in access, quality, and efficiency," said David Champeaux.

In hospitals, Amelia can have significant and immediate impact relieving those who should be caring for patients from routine interactions, by helping manage operational and administrative processes such as booking rooms and beds or coordinating patient transfers.

For chronic conditions, which account for 86%2 of healthcare spend in the US, Amelia can help health institutions establish sustainable delivery at scale of proactive, coordinated patient care plans. For example, she can streamline most administrative and operational arrangements, such as providing information, booking regular appointments and scheduling tests.

For health insurers, Amelia can help improve the customer experience and efficiency of routine member services. Amelia can deliver affordable 24/7 availability to answer eligibility and coverage questions, or initiate and manage claims. In parallel, by employing Amelia, health insurance providers will be able to connect back-end underwriting systems and processes to every customer conversation, delivering instant scale to their operations.

Amelia is the most human and comprehensive AI platform on the market. Uniquely, Amelia connects conversations to data and processes in order to provide a personalized service to every customer, at scale. Across the US, Europe and Asia, global organizations are employing Amelia to improve customer experience and drive enhanced productivity.

To learn more about how Amelia can transform business operations and customer interactions, visit ipsoft.com/amelia

About IPsoft
IPsoft automates IT and business processes for enterprises across a wide range of industries through the use of digital labor. Through its portfolio of world leading autonomic and cognitive solutions it provides services that allow its clients to secure competitive advantage. Headquartered in New York City, IPsoft has offices in 18 countries across the world and serves more than 500 of the world's leading companies directly as well as more than half of the world's largest IT services providers. To learn more about IPsoft's solutions please visit www.ipsoft.com.

Contacts

IPsoft
Daniela Zuin, 212-708-5521
Mobile: 917-822-0484
daniela.zuin@ipsoft.com
or
Finn Partners for IPsoft
Erica McDonald, 646-202-9784
Mobile: 732-713-2354
Erica.mcdonald@finnpartners.com

Frost & Sullivan, Artificial Intelligence & Cognitive Computing Systems in Healthcare

2 Centers for Disease Control and Prevention (CDC) Website Data




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IPsoft via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

LeoVegas AB: LeoVentures invests in esports betting - Pixel.bet13.9.2018 08:45Pressmeddelande

The LeoVegas Group, through its wholly owned investment company LeoVentures Ltd, has acquired 51% of the shares in Pixel Holding Group Ltd, which runs the esports betting operator Pixel.bet. The investment amounts to EUR 1.5 million for 51 percent of the company and is made through a new issue. Pixel.bet's vision is to create the greatest gaming experience in betting on esports www.pixel.bet "Esports is an international and fast-growing area that engages millions of viewers and players every month. With this investment in Pixel.bet we as a Group will gain unique insight into a new and fast-growing segment," comments Gustaf Hagman, LeoVegas' Group CEO and co-founder of LeoVegas Mobile Gaming Group. "In Pixel.bet we have found a passionate team of entrepreneurs who come from the esports community. With its strong technology and mobile-first gaming experience, Pixel.bet is a perfect match for the LeoVegas Mobile Gaming Group. Together we will drive development for the absolute premier exp

LeoVegas AB: LeoVentures investerar i esport betting - Pixel.bet13.9.2018 08:45Pressmeddelande

LeoVegas-koncernen har, genom sitt helägda investmentbolag LeoVentures Ltd förvärvat Pixel Holding Group Ltd, som driver esport betting operatören pixel.bet. Investeringen uppgår till 1,5 miljoner euro för 51 procent av bolaget och görs genom en nyemission. Pixel.bets vision är att skapa den främsta spelupplevelsen inom betting på esport www.pixel.bet "Esport är ett internationellt och snabbt växande område som engagerar miljontals tittare och utövare varje månad. Med investeringen i Pixel.bet får vi som koncern en unik inblick i ett nytt och snabbt växande segment.", säger Gustaf Hagman, Group CEO och co-founder av LeoVegas Mobile Gaming Group. "I Pixel.bet fann vi ett passionerat entreprenörsteam som verkligen kommer inifrån esport communityn. Med en riktigt bra teknik och spelupplevelse utvecklad mobile-first är det en perfekt match med LeoVegas Mobile Gaming Group. Tillsammans ska vi driva utveckling för den absolut främsta upplevelsen inom esport betting.", säger Robin Ramm-Ericso

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum